Icaritin Therapy for Platelet Dysfunction Bleeding Disorders

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current Western medicine lacks an effective, comprehensive treatment for bleeding disorders caused by platelet dysfunction, particularly those induced by thrombolytic or antithrombotic drugs, leading to complications such as hemorrhagic transformation and gastrointestinal bleeding, with limited curative effects.

Innovation Solution

Icaritin, a polyhydroxy flavonoid monomer, is used to promote platelet activation and aggregation, shorten thromboplastin time, and enhance blood coagulation, formulated into various pharmaceutical preparations for preventing and treating bleeding disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapy is used to treat ovarian cancer, then tumor cells are killed, but healthy cells are also damaged and side effects occur

Engineering Contradiction:

Improvetumor cell killing effectivenessVSAvoiddamage to healthy cells and side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by delivering chemotherapy drugs directly to the ovarian cancer site through a catheter implanted in the peritoneal cavity, allowing high concentration of drugs to act locally on tumor cells while minimizing systemic exposure and damage to healthy cells throughout the body

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses an intraperitoneal catheter as an intermediary device to deliver chemotherapy drugs directly to the peritoneal cavity where ovarian cancer typically occurs, serving as a mediator between the drug and the tumor site to achieve targeted delivery and reduce off-target effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If intraperitoneal chemotherapy is administered, then drug concentration at tumor site increases, but risk of infection and complications increases

Engineering Contradiction:

Improvedrug concentration at tumor siteVSAvoidrisk of infection and complications

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent applies preliminary action by implanting the intraperitoneal catheter before chemotherapy treatment begins, allowing the catheter tract to heal and establish a stable access route beforehand, thereby reducing the risk of infection during subsequent drug administrations

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent employs self-service mechanisms through the implanted catheter system that allows patients or caregivers to administer chemotherapy drugs at home without requiring hospitalization or surgical intervention for each treatment, reducing exposure to hospital-acquired infections while maintaining high drug concentrations at the tumor site

Inventive Principle:

Principle #25Self-service

Data Source

PatentEP4119139B1Icaritin for use in the treatment of a bleeding disorder caused by platelet dysfunction

Publication Date: 2026.05.13 LUNAN PHARMA GROUP CORPORATION

AI summary

The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.